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Case I
• 64 years old previously relatively fit and healthy female
• History of chronic constipation, gingivitis, anosmia
• Develops tremor, bradykinesia, voice changes, rigid facial expression,
stooped posture, loss of swinging of left arm, small cramped writing,
intermittent dystonia on hands and feet
• Diagnosed with Parkinson’s disease!

What is Parkinson’s
Disease?
Parkinson disease (PD) is a
chronic progressive
neurodegenerative disease of
the nervous system
characterized by the cardinal
features of rigidity,
bradykinesia, tremor and
postural instability.

Categories
1. Parkinsonism: a group of
disorders with Basal Ganglia
dysfunction
2. PD or idiopathic
Parkinsonism: The most
common form
3. Secondary Parkinsonism:
Viruses, toxins, drugs,
tumors
4. Parkinsonism plus
syndromes: conditions that
mimic PD, symptoms caused
by some other
neurodegenerative diseases

Etiology
• The mechanisms of PD remain elusive

• Several genes identified including SNCA, PARKIN, DJ-1, PINK-1, and
LRRK2 whose mutations are responsible for rare forms of Parkinson’s
disease.
• oxidative stress, mitochondrial and proteseomal dysfunction and
inflammatory system involvement
• ? Autoimmune disease

Signs and symptoms
Tremor
Subtle decrease in dexterity

Decreased arm swing on the first-involved side
Soft voice
Decreased facial expression
Sleep disturbances
Decreased sense of smell
Symptoms of autonomic dysfunction (eg, constipation, sweating
abnormalities, sexual dysfunction, seborrheic dermatitis)
A general feeling of weakness, malaise
Depression or anhedonia
Slowness in thinking

Diagnosis

PD is a clinical diagnosis

No laboratory biomarkers exist for the condition
Findings on routine (MRI) and (CT) scan are
unremarkable
MRI is useful to exclude strokes, tumors, multiinfarct state, hydrocephalus, and the lesions of
Wilson disease.

PET and DaT scans

Treatment
Symptomatic drug therapy
Levodopa/carbidopa: The gold standard of symptomatic
treatment
Monoamine oxidase (MAO)–B inhibitors
Other dopamine agonists (eg, ropinirole, pramipexole)
Anticholinergic agents (eg, trihexyphenidyl,
benztropine)

Treatment for non-motor symptoms
Sildenafil citrate (Viagra): For erectile dysfunction
Polyethylene glycol: For constipation
Modafinil: For excessive daytime somnolence
Methylphenidate: For fatigue (potential for abuse and
addiction)

Deep brain stimulation

Continuing Case I
Investigations
• FBC, U&E, LFT, Bone Profile, CRP: Normal
• MRI: Normal
• Stool comprehensive test: Candida overgrowth, low beneficial
bacteria
• Urine organic and amino acids: high benzoic acid, arabinase,
Citramalic Acid, Phenylacetic Acid (PAA), α-Hydroxyisobutyric Acid,
Pyroglutamic Acid
• Toxicity: PCB, pesticides, mercury, aluminum

Treatment
•
•
•
•
•
•
•
•
•
•
•

Nutrition: LCHF/ altered with ketogenic diet
Exercise
Optimizing gut flora
Treating candida overgrowth
Detoxification
Optimizing methylation pathway
Supplements ( glutathione precursors, antioxidants, anti-inflammatories)
Low dose naltrexone
Bioresonance & PEMFR
Non-laser light therapy
HBOT x 40 sessions

Unified Parkinson’s Disease Rating
Scale
I.
•
•
•

Mentation, Behavior and Mood
Intellectual Impairment
Thought Disorder
Depression

•

Motivation/Initiative

II. Activities of Daily Living
• Speech
• Salivation
• Swallowing
• Handwriting
• Cutting Food & Handling utensils
• Dressing
• Hygiene
• Falling
• Freezing when Walking
• Walking
• Tremor
• Sensory Complaints

At the time of diagnosis in 2012

2018

Moderate memory loss
Vivid dreams
Sustained depression with vegetative
symptoms (insomnia, poor appetite,
loss of interest)
Less assertive than usual

None
None
None

Normal
Normal
Normal
Moderately slow & small mostly legible
Can cut most foods with some difficulty
Needs assistance with buttoning &sleeves
Normal
Rare falling
Occasional freezing
Mild difficulty, no swing left arm
Moderate; bothersome to patient
Frequent painful sensations

Normal
Normal
Normal
Normal
Normal
Normal
Normal
None
None
Normal
Left leg-only when anxious
Occasional

Normal

Unified Parkinson’s Disease Rating
Scale
III. Motor Examination
Speech
Facial Expression
Tremor at Rest

Action or Postural Tremor of Hands
Rigidity
Finger Taps
Leg Agility
Arising from Chair
Posture
Gait
Postural Stability
Bradykinesia

At the time of diagnosis in 2012

2018

Monotone but understandable
Masked face, loss of facial express
Moderate in amplitude & present
most of the time
Slight; present with action
Marked, FROM full range of
achieved
Moderately impaired
Moderately impaired
Frequently unable to arise without
help
Moderately stooped posture
Short steps with shuffles
Impaired
Moderate slowness, small
amplitude of movement

Normal
Normal
Only left leg when anxious

None
Absent
Normal
Normal
Normal
Mostly normal
Normal
Normal
Minimal slowness

Unified Parkinson’s Disease Rating
Scale

At the time of diagnosis in 2012

2018

Dyskinesia

Daily

None

Early Morning Dystonia

Daily

None

Insomnia

Severe

Resolved

In summary:

6 years after diagnosis of PD
• Not on any PD medication
• Disease not progressing
• Significant improvement with complete resolution of majority of the symptoms

Case II
53 years old male, CEO
• 1. Parkinsonism (2005) / 40 years old
• 2. Reduced uptake in the left putamen and minimally reduced uptake
in the left caudate and right putamen (DAT scan December 2005)
• 3. Right hip replacement (July 2009)
• 4. Bilateral STN stimulators inserted (November 2012)
• 5. Medtronic ACTIVA PC box replacement (August 2017)
Present complaints: Painful dyskinesia, dystonia, left leg tremor,
walking with extreme difficulty, insomnia
Medications: Stalevo 125mg qds and Amantadine 100mg

Case II, Progress
Before HBOT

After 20 sessions of HBOT with no other
intervention

Upper body dyskinesia

30% improvement

Left leg tremor

50% improvement

walking with extreme difficulty & only short
distance

30% improvement

Severe rigidity, full range of motion achieved
with difficulty

50% improvement

Freezing when walking

50% improvement

Poor quality interrupted sleep

Sleeps well

• Numerous in vivo and in vitro studies confirms that HBOT induces
neurogenesis
• Wang XL. et al. [Hyperbaric oxygen promotes the migration and differentiation of endogenous neural
stem cells in neonatal rats with hypoxic-ischemic brain damage] Zhongguo Dang Dai Er Ke Za
Zhi. 2009;11(9):749–52. [PubMed]
• Zhang XY. et al. The role of beta-catenin signaling pathway on proliferation of rats neural stem cells after
hyperbaric oxygen therapy in vitro. Cell Mol Neurobiol. 2011;31(1):101–9. doi: 10.1007/s10571-0109559-z. [PubMed]
• Milosevic J. et al. Non-hypoxic stabilization of hypoxia-inducible factor alpha (HIF-alpha): relevance in
neural progenitor/stem cells. Neurotox Res. 2009;15(4):367–80. doi: 10.1007/s12640-009-9043z. [PubMed] [Cross Ref]
• Godman CA. et al. Hyperbaric oxygen treatment induces antioxidant gene expression. Ann N Y Acad
Sci. 2010;1197:178–83. doi: 10.1111/j.1749-6632.2009.05393.x. [PubMed]
• Yang YJ. et al. Hyperbaric oxygen induces endogenous neural stem cells to proliferate and differentiate in
hypoxic-ischemic brain damage in neonatal rats. Undersea Hyperb Med. 2008;35(2):113–29. [PubMed]
• Zhang T. et al. Hyperbaric oxygen therapy improves neurogenesis and brain blood supply in piriform
cortex in rats with vascular dementia. Brain Inj. 2010;24(11):1350–7. doi:
10.3109/02699052.2010.504525. [PubMed]
• Gunther A. et al. Reduced infarct volume and differential effects on glial cell activation after hyperbaric
oxygen treatment in rat permanent focal cerebral ischaemia. Eur J Neurosci. 2005;21(11):3189–94. doi:
10.1111/j.1460-9568.2005.04151.x. [PubMed]

Potential mechanisms of HBOT and HIF-1α.

Biomed Res Int. 2014;2014:308654. doi: 10.1155/2014/308654. Epub 2014 Jun 24.
Evidence of inflammatory system involvement in Parkinson's disease

Inflammatory factors involved in Parkinson’s disease
Cytokines and other soluble molecules

IL-1, IL-2, IL-4, IL-6, IL-10, TNF-, IFN-, TGF-, IL-6, MMP-3, IL-17, and
IL-18

Pattern recognition receptors (PRRs)

TLRs (TLR-1, -2, -3, and -7), NLRs, and complements

Immune cells

Microglia, monocyte, NK cell, T-cell, and B cell

Potential benefit of HBOT

Gut-Brain Axis

• Lewy pathology has been described in
neurons of the enteric nervous system in
nearly all Parkinson’s disease (PD) patients
at autopsy
• The enteric nervous system not only
contains a variety of functionally distinct
enteric neurons but also harbors a
prominent component of glial cells, the socalled enteric glial cells, which, like
astrocytes of the central nervous system,
contribute to support, protect, and
maintain the neural network
• recently shown that enteric glial cell
dysfunction occurs in PD.

Combining HBOT with other treatment modalities
• Nutrition: Ketogenic Diet?
• Optimizing gut microbiome
• Tailored supplements, vitamins and minerals
• Cannabidiol
• Low dose naltrexone
• Near infrared light therapy
• Repetitive transcranial magnetic stimulation
• Pulsed electromagnetic field therapy
• Exercise

Cannabidiol
• Two studies presented at the 21st International Congress of Parkinson’s
Disease and Movement Disorders further explored this possibility and
assessed the effects of oral cannabidiol (CBD) and inhaled cannabis in
patients with Parkinson’s disease.
• Maureen A. Leehey, MD, Professor of Neurology and Chief of the
Movement Disorders Division at the University of Colorado in Aurora,
and colleagues conducted a phase II, open-label, dose-escalation study
to evaluate the safety and tolerability of CBD (Epidiolex) in Parkinson’s
disease
• Over a 31-day treatment period, patients received 5-, 7.5-, 10-, 15-, and
20-mg/kg/day doses of CBD.
• 13 patients, mean total UPDRS score significantly decreased from 45.9 at
baseline to 36.4 at the final visit. UPDRS motor score decreased from
27.3 to 20.3. Mean rigidity from 9.14 to 6.29

• Laurie K. Mischley, ND, PhD, MPH, Associate Clinical Investigator at
Bastyr University Research Institute in Kenmore, Washington, and
colleagues evaluated the effect of inhaled cannabis on Parkinson’s
disease tremor using motion sensors and qualitative interviews.

LDN
• low-dose naltrexone blocks opioid receptors in the brain for few
hours and creates a “rebound effect,” resulting in up-regulated
production of the endogenous opioids beta-endorphin and metenkephalin, as well as increased expression of opioid receptors

• both endogenous and exogenous opioids immune modulators
• suppress microglial activation via its antagonistic effect on toll-like
receptor 4 (TLR4), a non-opioid receptor that is found on
macrophages such as microglia

Neuron Photomodulation-light therapy

Monitoring the progress of PD patients before, during and after
HBOT
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